BofA analyst Craig Bijou upgraded Globus Medical (GMED) to Neutral from Underperform with a price target of $97, up from $80, after the company preannounced Q4 revenue that was 3% above the Street ...

AUDUBON, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full ...

Globus Medical (NYSE:GMED – Get Free Report) last announced its earnings results on Tuesday, November 5th.The medical device company reported $0.83 earnings per share (EPS) for the quarter ...

Consensus $2.5B. “2024 was an exceptional year of execution and achievement for Globus Medical (GMED). With the NuVasive merger, we believe we created the strongest sales force and best product ...

Globus Medical AUDUBON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results ...

Analyst Ryan Zimmerman from BTIG maintained a Buy rating on Globus Medical (GMED – Research Report) and keeping the price target at $91.00. Ryan Zimmerman’s rating is based on a combination of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AUDUBON, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales results for the fourth ...